Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice

O’Shaughnessy, Joyce; Emens, Leisha A.; Chui, Stephen Y.; Wang, Wei; Russell, Kenneth; Lin, Shih-Wen; Flores Avile, Carlos; Luhn, Patricia; Schneeweiss, Andreas

doi:10.3390/curroncol28040239

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice

¹,

²,

³,

^4,†,

⁵,

³,

⁶

^3,*

and

Andreas Schneeweiss

⁷

Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX 75251, USA

UPMC Hillman Cancer Center, Magee-Womens Hospital, Pittsburgh, PA 15232, USA

Genentech, Inc., South San Francisco, CA 94080, USA

⁴

Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL 32610, USA

⁵

F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland

⁶

Genesis Research, Hoboken, NJ 07030, USA

⁷

National Center for Tumor Disease, Heidelberg University Hospital and German Cancer Research, 69120 Heidelberg, Germany

Author to whom correspondence should be addressed.

^†

Current affiliation: Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ 07033, USA.

Curr. Oncol. 2021, 28(4), 2741-2752; https://doi.org/10.3390/curroncol28040239

Received: 14 June 2021 / Revised: 14 July 2021 / Accepted: 15 July 2021 / Published: 17 July 2021

(This article belongs to the Section Medical Oncology)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

We investigated first-line (1L) treatment patterns and predictors of taxane use to better understand the evolving metastatic triple-negative breast cancer (mTNBC) treatment landscape. This retrospective analysis of the Truven Health MarketScan^® (Somers, NY, USA) Database included women with mTNBC who received 1L therapy within six months of diagnosis (January 2005–June 2015). Multivariate logistic regression models identified predictors of taxane use, adjusting for prognostic factors. A total of 2271 women with newly diagnosed mTNBC received 1L treatment during the study period. Half received a 1L taxane (53%), more often in combination than as monotherapy (58% versus 42%), though this varied by specific taxane. Nab-Paclitaxel monotherapy increased substantially after 2010. More recent treatment year (odds ratio, 2.16 (95% CI 1.69–2.76]) and number of metastases (≥3 versus 1: 1.73 (1.25–2.40)) predicted taxane monotherapy versus combination. Having a health maintenance organization versus a preferred provider organization plan predicted less nab-paclitaxel versus paclitaxel (0.32 (0.13–0.80)) or docetaxel (0.30 (0.10–0.89)) use. More recent index year (2011–2015 vs. 2005–2010) was the only predictor favoring nab-paclitaxel versus paclitaxel (2.01 (1.26–3.21)) or docetaxel (3.63 (2.11–6.26)). Taxane-containing regimens remained the most common 1L mTNBC treatments. Paclitaxel and nab-paclitaxel use changed substantially over time, with nab-paclitaxel use associated with insurance coverage. View Full-Text

Keywords: metastatic triple-negative breast cancer; chemotherapy; paclitaxel; nab-paclitaxel; docetaxel

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 164 KiB)

Share and Cite

MDPI and ACS Style

O’Shaughnessy, J.; Emens, L.A.; Chui, S.Y.; Wang, W.; Russell, K.; Lin, S.-W.; Flores Avile, C.; Luhn, P.; Schneeweiss, A. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. Curr. Oncol. 2021, 28, 2741-2752. https://doi.org/10.3390/curroncol28040239

AMA Style

O’Shaughnessy J, Emens LA, Chui SY, Wang W, Russell K, Lin S-W, Flores Avile C, Luhn P, Schneeweiss A. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. Current Oncology. 2021; 28(4):2741-2752. https://doi.org/10.3390/curroncol28040239

Chicago/Turabian Style

O’Shaughnessy, Joyce, Leisha A. Emens, Stephen Y. Chui, Wei Wang, Kenneth Russell, Shih-Wen Lin, Carlos Flores Avile, Patricia Luhn, and Andreas Schneeweiss. 2021. "Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice" Current Oncology 28, no. 4: 2741-2752. https://doi.org/10.3390/curroncol28040239

Find Other Styles

Article Metrics

Abstract views Pdf views Html views

Article Menu

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI